Figure 2. Genomic analyses of adavosertib with cisplatin in metastatic TNBC demonstrated immune pathway enrichment in patients with clinical benefit versus without (CB).

A) Breast cancer gene alterations in archival primary or metastatic tumors from 30 patients with targeted panel sequencing showed no clear association with response: each column represents a patient ordered from longest to shortest progression-free survival (PFS). B) Molecular Signature Database hallmark gene set enrichment analysis revealed immune gene set enrichment in patients with versus without CB at both biopsy (bx) timepoints on cisplatin monotherapy and on cisplatin WEE1 inhibitor (Cis WEE1i) combination therapy. C) Paired site-matched biopsy analysis of tumor infiltrating lymphocytes (TILs) measured by RNA sequencing indicated a nonsignificant increase in TILs in patients with but not without CB using paired Wilcoxon p values.

BL, baseline scans only as withdrew prior to treatment; CB, clinical benefit; Cis WEE1i, cisplatin WEE1 inhibitor; CR, complete response; FDR, false discovery rate corrected; L, line; NES, normalized enrichment score; PD, progressive disease; PR, partial response; SD, stable disease